Table 4.

SVR12 in hepatitis C virus genotype 1b-infected patients with and without resistance-associated polymorphisms at baseline (placebo-deferred treatment arm) n (%)

	All patients - placebo-deferred treatment arm
	With RAPs at baseline					Without RAPs at baseline
	Mainland China		Russia	South Korea	Overall	Mainland China	Russia	South Korea	Overall
NS5A-L31M/V		0	0	0	0	33/41 (80.5)	6/6 (100)	3/3 (100)	42/50 (84.0)
Y93H		2/8 (25.0)	0	0	2/8 (25.0)	31/33 (93.9)	6/6 (100)	3/3 (100)	40/42 (95.2)
L31M/V or Y93H		2/8 (25.0)	0	0	2/8 (25.0)	31/33 (93.9)	6/6 (100)	3/3 (100)	40/42 (95.2)
NS3-D168E		0	0	0	0	33/41 (80.5)	6/6 (100)	3/3 (100)	42/50 (84.0)

RAP: Resistance-associated polymorphism; SVR12: Sustained virologic response at posttreatment week 12.